PEEL-224 with chemo for teens and young adults with sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 49 years old
- You must weigh at least 40 kg (about 88 pounds)
- You must have a sarcoma that has returned or not responded to standard therapy
- You must have adequate organ function (bone marrow, kidneys, liver, heart)
- You must not have had prior treatment with PEEL-224
- You must agree to use effective contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy that targets a specific genetic change in Ewing sarcoma and a related rare tumor called DSRCT. It may be an option for patients whose cancer has come back, spread, or is very high-risk after standard chemotherapy.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This trial tests a personalized vaccine made from your tumor's unique gene fusion. It's for people with certain sarcomas that have spread and are now in remission or stable after standard treatment. The vaccine aims to help your immune system keep the cancer from coming back.
This trial tests a new drug called PEEL-224 combined with two chemotherapy medicines (vincristine and temozolomide) for children and young adults with certain solid tumors that have come back or not responded to treatment. It aims to see if this combination is safe and works against the cancer.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.